Peptide administration for lung fibrosis treatment using formulation based on medusa technology. develop a sustained release formulation os p144 or p17, loquid or freeze-dried form, for subcutaneous administration route and carry on preclinical and clinical trials.
To investigate the possibility of developing biomarkers for hcc prognosis and companion diagnostics by using advanced sequencing technologies (ngs) and the data analysis algorithms for a set of target biomarkers.
Development of CMTM6 inhibitors: Modulation of PDL1 for cancer treatment
Development of a comprehensive in silico platform for the prediction and analysis of protein - noble gas interactions and potential therapeutic applications across the entire human proteome.